Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:LIMN NASDAQ:MYNZ NASDAQ:NXTC NASDAQ:SCYX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLIMNLiminatus Pharma$1.19-1.7%$2.21$1.11▼$33.66$32.75MN/A915,716 shs208,398 shsMYNZMainz Biomed$1.55-0.6%$1.63$1.28▼$14.39$8.44M0.25512,691 shs174,913 shsNXTCNextCure$11.79+9.0%$5.96$2.69▼$19.20$28.96M1.3455,327 shs85,903 shsSCYXSCYNEXIS$0.78+1.3%$0.89$0.66▼$1.55$32.28M1.68666,837 shs370,464 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLIMNLiminatus Pharma-1.65%-11.85%-5.56%-81.61%+118,999,900.00%MYNZMainz Biomed-0.64%+0.65%-3.73%-25.48%-86.66%NXTCNextCure+8.96%+75.45%+109.04%+126.73%-26.68%SCYXSCYNEXIS+1.30%-3.99%-30.36%+6.27%-48.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLIMNLiminatus Pharma$1.19-1.7%$2.21$1.11▼$33.66$32.75MN/A915,716 shs208,398 shsMYNZMainz Biomed$1.55-0.6%$1.63$1.28▼$14.39$8.44M0.25512,691 shs174,913 shsNXTCNextCure$11.79+9.0%$5.96$2.69▼$19.20$28.96M1.3455,327 shs85,903 shsSCYXSCYNEXIS$0.78+1.3%$0.89$0.66▼$1.55$32.28M1.68666,837 shs370,464 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLIMNLiminatus Pharma-1.65%-11.85%-5.56%-81.61%+118,999,900.00%MYNZMainz Biomed-0.64%+0.65%-3.73%-25.48%-86.66%NXTCNextCure+8.96%+75.45%+109.04%+126.73%-26.68%SCYXSCYNEXIS+1.30%-3.99%-30.36%+6.27%-48.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLIMNLiminatus Pharma 1.00SellN/AN/AMYNZMainz Biomed 2.00Hold$14.00803.23% UpsideNXTCNextCure 2.25Hold$25.50116.28% UpsideSCYXSCYNEXIS 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest MYNZ, NXTC, SCYX, and LIMN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/14/2025MYNZMainz BiomedWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E)10/14/2025SCYXSCYNEXISWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025LIMNLiminatus PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025NXTCNextCureWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025LIMNLiminatus PharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025MYNZMainz BiomedWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025NXTCNextCureWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025SCYXSCYNEXISWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLIMNLiminatus PharmaN/AN/AN/AN/AN/AN/AMYNZMainz Biomed$890K9.42N/AN/A$2.61 per share0.59NXTCNextCureN/AN/AN/AN/A$28.06 per shareN/ASCYXSCYNEXIS$3.75M8.72N/AN/A$1.45 per share0.54Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLIMNLiminatus PharmaN/AN/A0.00∞N/AN/AN/AN/AN/AMYNZMainz Biomed-$21.65M-$65.60N/AN/AN/AN/AN/AN/AN/ANXTCNextCure-$55.65M-$25.82N/AN/AN/AN/A-106.62%-85.20%11/6/2025 (Estimated)SCYXSCYNEXIS-$21.29M-$0.40N/A15.60N/A-599.05%-43.04%-28.21%11/5/2025 (Estimated)Latest MYNZ, NXTC, SCYX, and LIMN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/6/2025Q3 2025NXTCNextCure-$4.06N/AN/AN/AN/AN/A11/5/2025Q3 2025SCYXSCYNEXIS-$0.21N/AN/AN/AN/AN/A10/3/2025Q2 2025LIMNLiminatus PharmaN/A-$0.05N/A-$0.10N/AN/A8/13/2025Q2 2025SCYXSCYNEXIS-$0.23-$0.14+$0.09-$0.14$0.15 million$1.36 million8/7/2025Q2 2025NXTCNextCure-$4.62-$11.29-$6.67-$11.29N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLIMNLiminatus PharmaN/AN/AN/AN/AN/AMYNZMainz BiomedN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/ASCYXSCYNEXISN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLIMNLiminatus PharmaN/A0.170.17MYNZMainz Biomed0.440.520.43NXTCNextCureN/A3.713.71SCYXSCYNEXISN/A5.205.20Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLIMNLiminatus PharmaN/AMYNZMainz BiomedN/ANXTCNextCure42.65%SCYXSCYNEXIS54.37%Insider OwnershipCompanyInsider OwnershipLIMNLiminatus PharmaN/AMYNZMainz BiomedN/ANXTCNextCure13.30%SCYXSCYNEXIS4.86%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableLIMNLiminatus PharmaN/A27.07 millionN/AN/AMYNZMainz Biomed305.41 millionN/ANot OptionableNXTCNextCure902.68 million2.32 millionOptionableSCYXSCYNEXIS6041.92 million39.89 millionOptionableMYNZ, NXTC, SCYX, and LIMN HeadlinesRecent News About These CompaniesSCYNEXIS (NASDAQ:SCYX) Earns "Sell (E+)" Rating from Weiss RatingsOctober 16, 2025 | americanbankingnews.comSCYNEXIS to Receive $22 Million Payment from GSK Following MARIO Study TerminationOctober 15, 2025 | quiverquant.comQSCYNEXIS and GSK Resolve Their Disagreement Related to the Restart of the Phase 3 MARIO StudyOctober 15, 2025 | globenewswire.comSCYNEXIS Announces Positive Results from a Phase 1, Single Ascending Dose and Multiple Ascending Dose Study of its Second-Generation Fungerp (SCY-247)September 30, 2025 | markets.businessinsider.comScynexis announces presentations highlighting data on SCY-247September 4, 2025 | msn.comSCYNEXIS to Present Promising Data on SCY-247's Antifungal Activity at TIMM-12 CongressSeptember 4, 2025 | quiverquant.comQSCYNEXIS Announces Multiple Presentations Highlighting Data from its Second-Generation Fungerp, SCY-247, at the 12th Congress on Trends in Medical Mycology (TIMM-12)September 4, 2025 | globenewswire.comSCYNEXIS to Participate in the H.C. Wainwright 27th Annual Global Conference September 8 – 10, 2025August 25, 2025 | markets.businessinsider.comScynexis reports Q2 EPS (14c), consensus (19c)August 14, 2025 | msn.comSCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 14, 2025 | finanznachrichten.deSCYNEXIS Reports Improved Financials Amidst Strategic DevelopmentsAugust 14, 2025 | msn.comSCYNEXIS Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 13, 2025 | globenewswire.comSCYNEXIS Inc. Advances Phase 3 Study for Invasive Candidiasis TreatmentAugust 8, 2025 | msn.comSCYNEXIS Resumes Dosing in Phase 3 MARIO Study Following FDA Hold, Triggering $10M Milestone Payment Dispute with GSKMay 30, 2025 | nasdaq.comSCYNEXIS, Inc. (SCYX) Resumes Phase III Dosing for Brexafemme After 19-Month FDA HoldMay 28, 2025 | insidermonkey.comSCYNEXIS Resumes Patient Dosing in Phase 3 MARIO StudyMay 28, 2025 | globenewswire.comSCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 15, 2025 | finance.yahoo.comScynexis to present preclinical data on SCY-247 at ESCMID MeetingApril 9, 2025 | markets.businessinsider.comSCYNEXIS Full Year 2024 Earnings: Misses ExpectationsMarch 14, 2025 | finance.yahoo.comSCYNEXIS Reports Full Year 2024 Financial Results and Provides Corporate UpdateMarch 12, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMYNZ, NXTC, SCYX, and LIMN Company DescriptionsLiminatus Pharma NASDAQ:LIMN$1.19 -0.02 (-1.65%) As of 10/21/2025 04:00 PM EasternLiminatus Pharma, Inc. is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.Mainz Biomed NASDAQ:MYNZ$1.55 -0.01 (-0.64%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$1.50 -0.05 (-3.23%) As of 10/21/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer. The company was founded in 2008 and is based in Mainz, Germany.NextCure NASDAQ:NXTC$11.79 +0.97 (+8.96%) Closing price 10/21/2025 03:59 PM EasternExtended Trading$11.90 +0.11 (+0.93%) As of 10/21/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.SCYNEXIS NASDAQ:SCYX$0.78 +0.01 (+1.30%) Closing price 10/21/2025 04:00 PM EasternExtended Trading$0.81 +0.03 (+3.46%) As of 10/21/2025 07:47 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SCYNEXIS, Inc., a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC. It also develops SCY-247 to treat systemic fungal diseases. The company has licensing and collaboration agreements with GlaxoSmithKline Intellectual Property (No. 3) Limited, Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC for the development, manufacture, and commercialization of ibrexafungerp. SCYNEXIS, Inc. was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. The company was incorporated in 1999 and is headquartered in Jersey City, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Micron Stock Could Soar 35% on AI Memory Demand WesBanco Insiders Signal Confidence With Coordinated Buys Will D-Wave's European Expansion Keep Fueling the Rally? Navitas Soars 78% on NVIDIA Update: Is This Rally Sustainable? Louis Vuitton Earnings Show Luxury Bull Market Isn’t Done Yet Waymo’s Global Expansion Strengthens the Case for GOOGL Stock Broadcom Inks OpenAI Deal: Why It's A Huge Win for AVGO Stock Meta vs OpenAI: Is Sora a True Threat to Meta's Dominance? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
